JOB SUMMARY

We are seeking a highly motivated Research Scientist, Bioanalytical Sciences & Assay Development to join our drug discovery team. This scientist will develop and implement mass spectrometry-based assays and bioanalytical workflows supporting Hit Identification (HitID), ADME/DMPK characterization, and physicochemical property assessment. A key focus will be the development and application of MS-based screening approaches for HitID, including Affinity Selection Mass Spectrometry (ASMS) and other MS-based capabilities.

The ideal candidate will have a strong foundation in bioanalytical science, mass spectrometry, and assay development, with the ability to develop robust and scalable assays for small-molecule drug discovery. This scientist will work at the interface of experimental science, automation, and AI-driven molecular design, generating high-quality data that inform compound optimization and enable rapid design–make–test–learn cycles. This position will be based in our San Diego Headquarters.

KEY RESPONSIBILITIES

Develop and implement MS-based assays and screening workflows for HitID, including ASMS and other MS-based approaches.
Develop fit-for-purpose bioanalytical and biochemical assays supporting screening, hit confirmation, and compound characterization.
Develop and execute in vitro ADME/DMPK assays, including metabolic stability, permeability, protein binding, and related endpoints.
Develop physicochemical property assays, including solubility, logD/lipophilicity, ePSA, and related measurements.
Develop and optimize LC-MS/MS bioanalytical methods and troubleshoot assay performance, sensitivity, selectivity, matrix effects, and reproducibility.
Develop automated and high-throughput assay workflows to improve capacity, turnaround time, and data quality.
Support operation and troubleshooting of MS and LC/MS instrumentation and associated laboratory automation.
Generate high-quality experimental datasets that support AI/ML-driven compound design and optimization.
Collaborate with biology, screening/HitID, medicinal chemistry, DMPK, and computational/AI teams to design assay strategies and translate experimental results into actionable insights.
Evaluate new assay technologies, MS methodologies, automation solutions, and data workflows to expand drug discovery capabilities.

QUALIFICATIONS

Ph.D. in Bioanalytical Chemistry, Mass Spectrometry, Chemical Biology, Drug Metabolism/Pharmacokinetics, Pharmaceutical Sciences, Biochemistry, or a related discipline, with approximately 0–5 years of relevant experience; or an M.S. with significant relevant industry experience.
Strong foundation in mass spectrometry, bioanalytical science, and assay development, preferably with hands-on LC-MS/MS experience.
Demonstrated experience developing, optimizing, and troubleshooting bioanalytical, biochemical, or screening assays.
Strong understanding of quantitative assay design, experimental controls, data quality, and troubleshooting.
Strong scientific problem-solving and collaboration skills, with an interest in connecting experimental data with AI/ML-enabled drug discovery and molecular design.

PREFERRED QUALIFICATIONS

Experience with MS-based screening or HitID approaches, including ASMS or related technologies, is highly desirable.
Experience with in vitro ADME/DMPK and/or physicochemical property assays such as solubility, logD, and ePSA is preferred.
Experience with SCIEX, Agilent, Thermo, or comparable MS/LC-MS platforms is desirable.
Experience with laboratory automation, high-throughput screening/experimentation, or automated data processing is a plus.

ABOUT IAMBIC THERAPEUTICS

Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at iambic.ai.

MISSION & CORE VALUES

Our mission is to deliver better medicines through innovations in AI-based discovery technologies. The culture and work at Iambic Therapeutics are profoundly strengthened by the diversity of our people and our differences in background, culture, national origin, religion, sexual orientation, and life experiences. We are committed to building an inclusive environment where a diverse group of talented humans work together to discover therapeutics and create technologies.

PAY AND BENEFITS

We offer industry leading competitive pay, company paid healthcare, flexible spending accounts, voluntary life insurance, 401K matching, and uncapped vacation to our team. We are in a brand-new state-of-the art facility in beautiful San Diego with an onsite gym, dining, and easy access to great places to live and play.

About the company

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify's Take

What believers are saying

Iambic filed an IPO on September 21, 2026, after $207.9 million cash.
Revenues reached $18 million over the twelve months ended June 30, 2026.
ClinicalTrials.gov shows IAM1363 recruiting 383 patients across 53 sites, including EU expansion.

What critics are saying

IAM1363 remains unproven; Phase 1 completion sits in 2028, delaying any approval.
Iambic's revenue still depends on partnerships; AbbVie and IPO proceeds fund the burn.
If AbbVie walks and IAM1363 fails, Iambic becomes a platform story without assets.

What makes Iambic Therapeutics unique

Enchant v3 spans 6,000+ molecular properties across 16 modalities, compressing discovery cycles.
AbbVie's September 21, 2026 collaboration validates Iambic's platform with another pharma heavyweight.
IAM1363 reached Phase 1 from AI design, proving platform-to-clinic execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
401(k) Company Match
Unlimited Paid Time Off

Growth & Insights and Company News

6 month growth

1 year growth

-2%

2 year growth

-3%

Antlers American

Oct 14th, 2026

Iambic prices $150M IPO at $16 per share, files IND for brain-penetrant cancer drug IAM217

Iambic Therapeutics, an AI-driven drug developer, priced its initial public offering at $16.00 per share, selling 9,375,000 shares for expected gross proceeds of $150.0 million. The underwriters have a 30-day option to buy up to 1,406,250 more shares. Shares are expected to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker "IAM." The offering is due to close on October 16, 2026. J.P. Morgan, Jefferies, BofA Securities, and Citigroup are joint book-running managers. Iambic also submitted an Investigational New Drug application to the US Food and Drug Administration for IAM217, a potentially brain-penetrant KIF18A inhibitor. The Phase 1/2 trial would target triple-negative breast cancer, ovarian cancer, and other solid tumours. In a preclinical model, IAM217 produced about 90% regression of established intracranial tumours.

Intelligence360

Oct 5th, 2026

Iambic Therapeutics raises $66.5M to advance AI-driven drug discovery platform

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission to raise $66.5 million in new funding. The filing was made under Regulation D or Section 4(a)(5) of the Securities Act of 1933, which allows companies to sell securities without registration. Iambic Therapeutics is a drug discovery company that uses AI and automated chemistry and biology experimentation to accelerate pharmaceutical development. The company's platform integrates proprietary AI technologies, including Enchant and NeuralPLexer, for multimodal endpoint prediction. The company previously advanced a novel drug candidate to clinical trials in approximately two years and maintains a diverse preclinical pipeline. Iambic is led by Chief Executive Officer Tom Miller.

PR Newswire

Sep 21st, 2026

AbbVie partners with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience and oncology

AbbVie and Iambic Therapeutics have entered into a multi-year collaboration to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology. The partnership will combine Iambic's molecular superintelligence platform with AbbVie's therapeutic expertise to develop small molecule therapies with first-in-class and best-in-class potential. The collaboration will utilise Enchant v3, Iambic's next-generation multimodal transformer model trained on over 6,000 molecular properties. This technology is designed to optimise candidate properties simultaneously, reducing drug discovery timelines whilst improving success rates. Under the agreement, Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The partnership aims to accelerate the discovery process and deliver breakthrough medicines to patients more quickly.

Associated Press

Sep 21st, 2026

Iambic unveils Enchant v3 AI model with 41B parameters to accelerate drug discovery

Iambic, a clinical-stage life science and technology company, has launched Enchant v3, the latest version of its AI-driven multimodal transformer model for drug discovery and development. The model features 41 billion parameters and has been pretrained on 4.5 trillion tokens. Enchant v3 can predict more than 6,000 molecular properties across 16 biomedical modalities, including text, assay data, molecule structure, protein structure, images, multi-omics, biologics, clinical trial data, and pharmacokinetics. The system is designed to integrate diverse data sources and improve prediction accuracy as the model scales. Iambic initially launched Enchant in 2024. The company says its platform combines AI with automated chemistry and biology experimentation, and it previously discovered a novel drug candidate that advanced to clinical trials in approximately two years.

Intelligence360 News

Dec 3rd, 2025

Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics

Research Scientist 1/2 - Bioanalytical Sciences & Assay Development

About the job